Diaceutics Launches Enhanced
Rare-Disease Offering
Significant expansion of lab
network will deliver more rare-disease data
New contract signed to
support the commercialisation of a rare-disease
therapy
Belfast and
London, 27 August 2024 - Diaceutics PLC (AIM:
DXRX), a leading technology and solutions provider to the pharma
and biotech industry, is pleased to announce a significant
enhancement to its offering which has facilitated a new
rare-disease contract win. Access to this new data will
revolutionise the early identification of patients, a crucial
growth area for pharma companies developing therapies for
rare-diseases. Leveraging cutting-edge data utilisation, it will
improve earlier patient diagnosis and ultimately, clinical
outcomes.
Driving this enhancement are 3 key developments
within the Diaceutics business as follows:
1.
|
Onboarding of
New Data Partners: A number of new rare-disease
genomic lab data partners have joined the DXRX network. These
partners specialise in genetic testing, including the largest
recognised testing lab in the United States for genetically
acquired rare diseases.
|
|
|
2.
|
Advanced Lab
Labelling Natural Language Processing (NLP):
Diaceutics has updated its advanced lab labelling NLP process
to standardise and add value to the new data. This process enables
complex labelling such as pathogenic vs Variants of Unknown
Significance (VUS) variant calling which until now has proven
challenging for the industry to identify.
|
|
|
3.
|
Access to
Additional Industry Experts: The company now
has a team of industry experts with deep rare-disease experience to
support biopharma business opportunities and ensure clients derive
maximum value from Diaceutics' deep-data offering.
|
Jordan Clark,
Chief Data Officer of Diaceutics commented:
"These enhancements to our
rare-disease data offering represent significant progress in our
mission to support the earlier identification and treatment of
patients with rare diseases. By integrating new data, advanced
labelling and a specialised team, we are well-positioned to address
the critical needs of this underserved market and help patients in
need."
Susanne Munksted, Chief Precision Medicine
Officer of Diaceutics, commented: "Diaceutics is uniquely positioned to support
pharma clients in the challenging and complex area of rare
diseases. Our business model is unique in that we combine best in
class data with disease experts who have a passion for precision
medicine and improving patient outcomes."
Despite medical and scientific
advances, diagnosing rare diseases remains a significant challenge
for biopharma companies. Many patients face years of multiple
referrals, inconclusive test results and limited treatment
benefits. Early diagnosis and quick interventions are crucial for
patient survival and quality of life. A precision medicine approach
can end these diagnostic odysseys and open opportunities for better
clinical outcomes for patients in need.
The strategic enhancements announced today will
enable Diaceutics to identify more patients earlier and in doing
so, help pharma customers to better commercialise gene therapies
for rare diseases. Leveraging these business enhancements,
Diaceutics has already secured a new contract to provide a
multi-product solution to support the commercialisation of a
therapy in a rare autosomal-recessive disease. This initial
contract win demonstrates Diaceutics' ability to meet the complex
needs of this market.
This announcement contains inside information
for the purposes of Article 7 of Regulation (EU) 596/2014 as it
forms part of UK domestic law by virtue of the European Union
(Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with
the Company's obligations under Article 17 of MAR. The person
responsible for making this announcement on behalf of the Company
is Nick Roberts, Chief Financial Officer.
About
Diaceutics
At Diaceutics we believe that every patient
should get the opportunity to receive the right test and the right
therapy to positively impact their disease outcome. We provide the
world's leading pharma and biotech companies with an end-to-end
commercialisation solution for precision medicines through data
analytics, scientific and advisory services enabled by our platform
DXRX - The Diagnostics Network®.
Enquiries:
Diaceutics PLC
|
|
Ryan Keeling, Chief Executive
Officer
Nick Roberts, Chief Financial
Officer
|
Tel: +44 (0)28 9040 6500
investorrelations@diaceutics.com
|
|
|
Stifel Nicolaus Europe Limited (Nomad &
Broker)
|
Tel: +44 (0)20 7710
7600
|
Ben Maddison, Nick
Harland, Kate Hanshaw
|
|
|
|
Alma Strategic Communications
|
Tel: +44(0)20 3405
0205
|
Caroline Forde, Kinvara Verdon,
Kieran Breheny
|
diaceutics@almastrategic.com
|
|
|